Similarly, our cohort included patients with predominantly normal liver function tests at baseline but also potentially mild hepatitis (ALT levels < 2 ULN according to clinical guidelines allowing these mild elevations for ICB therapy). The gene discussed is GPT; the disease is hepatitis A virus infection.